Jan. 01, 2026 4:41 AM ETRigel Pharmaceuticals, Inc. (RIGL) StockBiologicsInvesting Group LeaderCommentsSummaryRigel Pharmaceuticals delivered strong 2025 results, with Q3 revenue of $69.5M, net income of $27.9M, and cash of $137.1M.RIGL raised 2025 revenue guidance to $285M–$290M, projecting 55%–59% commercial growth, driven by TAVALISSE, REZLIDHIA, and GAVRETO.2026 is expected to be a transition year, with flat revenue and declining EPS due to higher R&D spend, before a return to double-digit growth in 2027.I maintain a conviction level of 3/5, plan disciplined position sizing, and will monitor OpEx, product trends, and clinical progress closely.Looking for a helping hand in the market? Members of Compounding Healthcare get exclusive ideas and guidance to navigate any climate.